Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Royalty Pharma Earnings Call: Key Takeaways

Royalty Pharma raised 2026 guidance for the third consecutive quarter, driven by 12% year-to-date royalty receipt growth and strong clinical success across its development-stage portfolio.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthRoyalty receipts grew 12% YTD; portfolio receipts grew 9% in Q3.
Mgmt ConfidenceHigh; raised guidance for third consecutive quarter citing excellent business momentum.
Demand VisibilityRobust deal pipeline supported by $1 trillion expected biopharma R&D spend.
Margin TrendsAdjusted EBITDA margin 82% year-to-date; operating costs 5.6% of receipts.
Op. LeverageInternalization of manager in 2025 delivering significant cash savings.
Vol vs PriceGrowth driven by diversified portfolio performance and new royalty acquisitions.
Segment GrowthTremfya, Erleada, Evrisdy, and Orserdu were key growth drivers.
New ClientsNew R&D co-funding deals with J&J and Teva totaling $1 billion.
Capex & DebtDeployed $1.6B YTD; $8.8B investment-grade debt; 2.5x net leverage.
RegulatorySix FDA approvals and three filings in 2026; 90% development success.
CommentaryFocusing on being the premier capital allocator in life sciences innovation.
New LaunchesFDA approvals for Voronigo (schizophrenia) and Augtyro (pancreatic cancer).

Growth

Portfolio receipts grew 9% to $890 million; royalty receipts grew 12% year-to-date.

Outlook

Raised 2026 portfolio receipts guidance to $3.5B-$3.55B; targeting $4.7B top line by 2030.

Risks

Management provided limited specifics on Alpassaran economics following the Pelacarsin Phase 3 failure.

Source

The company's earnings call, NASDAQ: RPRX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Royalty Pharma plc: key numbers

Share price
$68.53Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Royalty Pharma plc

All →
9:08 AM ET 10-Q
Financial Results ▶ Call

Royalty Pharma Q3 2026 Results: Net Income $145M, Down 49.1% YoY

Royalty Pharma reported total income and other revenues of $1.99 billion for the first nine months of 2026, up from $1.76 billion in the prior year period. Despite the revenue growth, consolidated net income for the nine-month period decreased to $816.4 million from $967.3 million, primarily due to higher interest expenses and a $219.8 million impairment on financial royalty assets.

Key figure
Net income $145M · -49.1% YoY
7:39 AM ET 8-K
Financial Results

Royalty Pharma Financial Results

Royalty Pharma reported 9% growth in Portfolio Receipts to $890 million for the third quarter of 2026, driven by strong performance from Tremfya, Voranigo, and Evrysdi. The company raised its full-year 2026 Portfolio Receipts guidance to a range of $3.50 billion to $3.55 billion. Management highlighted $1.9 billion in announced transactions year-to-date, including new royalties on Zoryve and Mimrylo.

Term
Q3 2026

“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance. We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra.”

Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board
5:13 PM ET Form 4
Insider Selling

Royalty Pharma EVP, Research & Investments Marshall Urist Sells $236K of Stock

Marshall Urist, EVP, Research & Investments, sold 4,126 shares of Royalty Pharma plc at $57.10 a share, worth $236K in total on Oct 5, 2026. Shares held after the trade: 0 (-100.0%).

Value
$236K
Shares
4,126
Price
$57.10
Role
EVP, Research & Investments
Holding change
-100.0%
Trade date
Oct 5, 2026
4:32 PM ET Form 4
Insider Selling

Royalty Pharma EVP, Research & Investments Marshall Urist Sells $239K of Stock

Marshall Urist, EVP, Research & Investments, sold 4,126 shares of Royalty Pharma plc at $57.88 a share, worth $239K in total on Sep 28, 2026. Shares held after the trade: 4,126 (-50.0%).

Value
$239K
Shares
4,126
Price
$57.88
Role
EVP, Research & Investments
Holding change
-50.0%
Trade date
Sep 28, 2026
4:12 PM ET Form 4
Insider Selling

Royalty Pharma EVP & Chairman, Partnering Christopher Hite Sells $5.85M of Stock

Christopher Hite, EVP & Chairman, Partnering, sold 100,000 shares of Royalty Pharma plc at $58.51 to $58.93 a share (average $58.53) in 2 transactions, worth $5.85M in total on Sep 22, 2026. Shares held after the trade: 270,401 (-1.4%).

Value
$5.85M
Shares
100,000
Average price
$58.53
Role
EVP & Chairman, Partnering
Holding change
-1.4%
Trade date
Sep 22, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.